Literature DB >> 22323561

Mitochondrial function and content in pheochromocytoma/paraganglioma of succinate dehydrogenase mutation carriers.

E Rapizzi1, T Ercolino, L Canu, V Giaché, M Francalanci, C Pratesi, A Valeri, M Mannelli.   

Abstract

To date, the consequences of succinate dehydrogenase (SDH) impairment on overall mitochondrial functions are still obscure. In this study, we evaluated SDH activity and expression and mitochondrial homeostasis in 57 tissue samples of pheochromocytoma (PHEO)/paraganglioma (PGL) obtained from patients genotyped for PHEO/PGL susceptibility genes. The resulted SDH activity and content always decreased in SDH-mutated tumors, in one out of two MAX-mutated patients and in four patients resulted wild type (wt) at genetic screening. All these four wt patients were further screened for large deletions in SDH genes, TMEM127 and MAX and resulted wt but two had somatic SDHD mutations. The RT-PCR in the MAX-mutated sample suggests that the decrease in SDH depends on complex instability and not on a reduced SDHB expression. SDH mutations neither alter citrate synthase (CS) activity nor the content of voltage-dependent anion channel (VDAC) while the expression of the mitochondrial complex IV (cytochrome c oxidase (COX)) was found extremely variable in all (mutated and wt) samples suggesting an impairment of mitochondrial cristae in these tumors. In conclusion, tumors from patients with germ line SDH mutations invariably show decreased enzymatic activity and content, but an SDH impairment may also depend on SDH somatic mutations or, seemingly, on MAX mutations. The impaired SDH activity in the two wt tissues suggests mutations in other still unknown susceptibility genes. Finally, the extreme variability in COX expression levels is yet to be explained and this strongly suggests to evaluate other mitochondrial features to better understand the mitochondrial role in the pathogenesis of these tumors.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22323561     DOI: 10.1530/ERC-11-0263

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  8 in total

Review 1.  Current views on cell metabolism in SDHx-related pheochromocytoma and paraganglioma.

Authors:  Ales Vicha; David Taieb; Karel Pacak
Journal:  Endocr Relat Cancer       Date:  2014-05-08       Impact factor: 5.678

2.  Genotype-specific differences in the tumor metabolite profile of pheochromocytoma and paraganglioma using untargeted and targeted metabolomics.

Authors:  J U Rao; U F H Engelke; F C G J Sweep; K Pacak; B Kusters; A G Goudswaard; A R M M Hermus; A R Mensenkamp; G Eisenhofer; N Qin; S Richter; H P M Kunst; H J L M Timmers; R A Wevers
Journal:  J Clin Endocrinol Metab       Date:  2014-12-02       Impact factor: 5.958

3.  Germline SUCLG2 Variants in Patients With Pheochromocytoma and Paraganglioma.

Authors:  Katerina Hadrava Vanova; Ying Pang; Linda Krobova; Michal Kraus; Zuzana Nahacka; Stepana Boukalova; Svetlana D Pack; Renata Zobalova; Jun Zhu; Thanh-Truc Huynh; Ivana Jochmanova; Ondrej Uher; Sona Hubackova; Sarka Dvorakova; Timothy J Garrett; Hans K Ghayee; Xiaolin Wu; Bjoern Schuster; Philip E Knapp; Zdenek Frysak; Igor Hartmann; Naris Nilubol; Jiri Cerny; David Taieb; Jakub Rohlena; Jiri Neuzil; Chunzhang Yang; Karel Pacak
Journal:  J Natl Cancer Inst       Date:  2022-01-11       Impact factor: 13.506

4.  Krebs cycle metabolite profiling for identification and stratification of pheochromocytomas/paragangliomas due to succinate dehydrogenase deficiency.

Authors:  Susan Richter; Mirko Peitzsch; Elena Rapizzi; Jacques W Lenders; Nan Qin; Aguirre A de Cubas; Francesca Schiavi; Jyotsna U Rao; Felix Beuschlein; Marcus Quinkler; Henri J Timmers; Giuseppe Opocher; Massimo Mannelli; Karel Pacak; Mercedes Robledo; Graeme Eisenhofer
Journal:  J Clin Endocrinol Metab       Date:  2014-07-11       Impact factor: 5.958

5.  Succinate dehydrogenase subunit B mutations modify human neuroblastoma cell metabolism and proliferation.

Authors:  Elena Rapizzi; Tonino Ercolino; Rossella Fucci; Benedetta Zampetti; Roberta Felici; Daniele Guasti; Andrea Morandi; Elisa Giannoni; Valentino Giaché; Daniele Bani; Alberto Chiarugi; Massimo Mannelli
Journal:  Horm Cancer       Date:  2014-03-05       Impact factor: 3.869

6.  Genotype-specific abnormalities in mitochondrial function associate with distinct profiles of energy metabolism and catecholamine content in pheochromocytoma and paraganglioma.

Authors:  Jyotsna U Rao; Udo F H Engelke; Richard J T Rodenburg; Ron A Wevers; Karel Pacak; Graeme Eisenhofer; Nan Qin; Benno Kusters; Angelina G Goudswaard; Jacques W M Lenders; Ad R M M Hermus; Arjen R Mensenkamp; Henricus P M Kunst; Fred C G J Sweep; Henri J L M Timmers
Journal:  Clin Cancer Res       Date:  2013-05-30       Impact factor: 12.531

7.  SDHB knockout and succinate accumulation are insufficient for tumorigenesis but dual SDHB/NF1 loss yields SDHx-like pheochromocytomas.

Authors:  Neali Armstrong; Claire M Storey; Sarah E Noll; Katherine Margulis; Myat Han Soe; Haixia Xu; Benjamin Yeh; Lauren Fishbein; Electron Kebebew; Brooke E Howitt; Richard N Zare; Julien Sage; Justin P Annes
Journal:  Cell Rep       Date:  2022-03-01       Impact factor: 9.995

8.  Novel Germline PHD2 Variant in a Metastatic Pheochromocytoma and Chronic Myeloid Leukemia, but in the Absence of Polycythemia.

Authors:  Aldesia Provenzano; Massimiliano Chetta; Giuseppina De Filpo; Giulia Cantini; Andrea La Barbera; Gabriella Nesi; Raffaella Santi; Serena Martinelli; Elena Rapizzi; Michaela Luconi; Mario Maggi; Massimo Mannelli; Tonino Ercolino; Letizia Canu
Journal:  Medicina (Kaunas)       Date:  2022-08-17       Impact factor: 2.948

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.